Badalona

• Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) Recruiting
  2023-508105-24-00 5 2021-11-11 COVID-19
• The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoemboli … Recruiting
  2024-512953-26-00 5 2021-07-06 intermediate-stage hepatocellular carcinoma
• Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting
  2024-512982-15-00 5 2021-06-28 BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuz … Recruiting
  2023-507728-22-00 3 2021-06-25 Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
• Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negativ … Recruiting
  2024-515063-66-00 4 2021-03-30 Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects wi … Recruiting
  2024-514010-12-00 1 2020-12-03 Advanced Malignancies
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination with Cemiplimab in Adult Patients with Recurrent Ovarian Cancer or Other … Recruiting
  2024-510783-23-00 7 2020-10-29 Fallopian Tube Cancer
• Clinical trial to evaluate safety and effectiveness of APL-101 for the treatment of advanced MET expressing solid tumors, including Non-Smal … Recruiting
  2024-514542-37-00 9 2020-08-13 Select advanced solid tumors and Non-Small Cell Lung Cancer with MET a
• An experimental study in adults and adolescents who underwent stem cell transplantation and developed a Graft versus Host Disease after ster … Recruiting
  2023-505737-26-00 5 2020-07-22 Steroid refractory Acute Graft versus host Disease
• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 4 2020-05-05 Pan tumor
• BRCA-P: A Cancer Prevention study to determine if Denosumab can prevent Breast Cancer Development in Women carrying a BRCA1 Germline Mutatio … Recruiting
  2024-513734-38-00 5 2019-07-03 Prevention of breast cancer in women with a BRCA1 germline mutation
• An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) Recruiting
  2024-515690-10-00 9 2019-05-10 Follicular B-cell non-Hodgkin's lymphoma
• A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting
  2023-508302-24-00 4 2019-05-07 Locally Advanced/Metastatic Urothelial Cancer
• Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting
  2023-504201-36-00 10 2018-12-21 Defined by parent protocol. The study will enroll all adult and paedia
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting
  2022-502706-33-00 6 2018-01-10 Patients with invasive breast cancer in early stages
• A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent … Recruiting
  2023-505625-14-00 7 2017-01-31 Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
• Autologous tolerogenic dendritic cells (ATDC) for highly sensitized kidney transplant recipients Ended recruitment
  2024-519978-39-00 3 2026-04-17 Kidney trasplants
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended recruitment
  2025-521918-26-00 4 2026-02-11 HIV Infections
• Safety, tolerance and antiretroviral activity of IMP: a pilot clinical trial in patients with recent HIV-1 infection Ended recruitment
  2024-519641-30-00 4 2026-01-26 Asymptomatic patients with recent HIV-1 infection
• Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part … Ended recruitment
  2023-506146-23-00 4 2025-11-17 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
• Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris … Ended recruitment
  2023-508827-10-00 4 2025-10-13 Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
• An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachmen … Ended recruitment
  2025-520629-19-00 3 2025-10-01 HIV Infections

Showing 337–360 of 775 trials